- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Anti-Mullerian Hormone: Usefulness in Clinical Practice
Call for Papers
Anti-Mullerian hormone (AMH) is a protein that inhibits the development of the Mullerian ducts (paramesonephric ducts) in the male embryo. AMH prevents the development of the Mullerian ducts into the uterus and other Mullerian structures in the first 8 weeks of gestational age. AMH is produced by granulosa cells of the ovary during the reproductive years and controls the formation of primary follicles by inhibiting excessive follicular recruitments by FSH.
Whereas AMH is nearby undetectable in females at birth, the level is very stable in healthy young women from puberty to the age of 30 years.
Some illnesses are correlated with elevated (PCOS) or lower AMH levels (climax praecox). Additionally some studies have shown that the dose of stimulation in assisted reproduction is reverse correlated to the AMH levels. Because of this correlation, some authors stated that the AMH gives a good impression about the follicular reserve of the ovarian.
The aim of this special issue is to summarize the actual view and the clinical aspects of this interesting hormone. It should also show the limits of AMH as a diagnostic tool, especially to avoid wrong therapeutic recommendations to patients.
We would like to invite investigators to contribute original research articles as well as review articles that will give more information about the role of anti-Mullerian hormone in the following. Potential topics include, but are not limited to:
- Ovarian reserve
- Diagnosis in fertility treatment
- Risk calculation of fertility
- Correlation of early measuring to the diagnosis of climax praecox
- Treatment in assisted reproductive medicine
We appreciate also articles about the pathophysiological background.
Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ije/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/author/submit/journals/ije/amull/ according to the following timetable:
|Manuscript Due||Friday, 10 May 2013|
|First Round of Reviews||Friday, 2 August 2013|
|Publication Date||Friday, 27 September 2013|
Lead Guest Editor
- Kai J. Buhling, Department of Gynecological Endocrinology, Clinic of Gynecology, University Hospital Hamburg-Eppendorf, Hamburg, Germany